The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific

Journal of Cardiovascular Surgery

Volumn 39, Issue 1, 1998, Pages 1-7

  Castier, Y ^a   Chemla, E ^a   Nierat, J ^b   Heudes, D ^a   Vasseur, M A ^a   Rajnoch, Ch ^a   Bruneval, P ^a   Carpentier, A ^a   Fabiani, J N ^a  

^a HÔPITAL BROUSSAIS   (France)

^b SANOFI   (France)

Author keywords

Hyperplasia prevention and control; Oligonucleotides, antisense; Tunica intima pathology

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GUANOSINE;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; INTIMA; MALE; ONCOGENE C MYB; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, ABDOMINAL; CELL DIVISION; DNA-BINDING PROTEINS; DOUBLE-BLIND METHOD; HYPERPLASIA; MALE; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYB; RANDOM ALLOCATION; RATS; RATS, WISTAR; TRANS-ACTIVATORS; TUNICA INTIMA;

EID: 0031884924     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hermans R, Rensing B, Strauss B, Serruys P. Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a magic bullet. Am Heart J 1991;122:171-87.
2. Ip J, Fuster V, Badimon L, Badimon J, Taubman M, Chesebro J. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle proliferation. J Am Coll Cardiol 1990;15:1667-87.
3. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation 1992;80:43-6.
4. Clowes A, Reidy M, Clowes M. Kinetics of cellular proliferation after arterial injury. Lab Invest 1983;49:327-33.
5. Schwanz S, Campbell G, Campbell J. Replication of smooth muscle cells in vascular disease. Circ Res 1986;58:427-44.
6. Franklin S, Faxon D. Pharmacological prevention of restenosis after coronary antioplasty: review of randomized clinical trials. Coronary Artry Dis 1993;4:232-42.
7. Popma J, Califf R, Topol E. Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426-36.
8. Kindy M, Sonnenshein G. Regulation of oncogene expression in cultured aortic smooth muscle cells. J Biol Chem 1986;261:12865-8.
9. Gondna T, Metcalf D. Expression of myb, myc and fos proto-oncogenes during the differentiation of a murine myeloid leukemia. Nature 1984;310:249-51.
10. Brown K, Kindy M, Sonenshein G. Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cell. J Biol Chem 1992;267:249-51.
11. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agent - is the bullet really magical? Science 1993;261:1004-11.
12. Wagner R, Gene inhibition using antisense oligodeoxynucleotide. Nature 1994;372:333-5.
13. Simons M, Edelmaner ER, Dekeyser JL, Lunger R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in viva. Nature 1992;359:67-70.
14. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res 1992;70:835-43.
15. Bennet MR, Anglin S, McEwan JR, Jagoe R, Newby AC, Evan GI. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994;93:820-8.
16. Shi Y, Hutchinson H, Hall D, Zalewski A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 1993;88:1190-5.
17. Shi Y, Fard A, Galeo A. Transcatheter delivery of c-myc antisense oligomers reduces nuointimal fonnation in a porcine model of coronary artery balloon injury. Circulation 1994;90:944-51.
18. Biro S, Fu Y, Vu Z, Epstein S. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA 1993;90:654-8.
19. Burgess T, Fisher E, Ross S. The antiprotiferative activity of c-myb and antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995;92:4051-5.
20. Villa A, Guznian L, Poptic E. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995;76:505-13.
21. Edelman E, Simon M, Sirois M. Rosenberg R. c-myc in vasculoproliferative disease. Circ Res 1995;76:176-82.
22. Rakugi H, Kim D, Krieger J, Wang D, Dzau V, Pratt R. Induction of angiotensin converting enzyme in the neointima after vascular injury. J Clin Invest 1994;93:339-46.
23. Stemerman M, Weinstein R, Rowe J, Maciag T, Fuhro R, Gardner R. Vascular smooth muscle growth kinetics in viva in aged rats. Proc Natl Acad Sci USA 1982;79:3863-6.
24. Villa AE, Guzman LA, Poptic E. Local delivery of antisence c-myb for prevention of neo-intimal proliferation after balloon arterial injury. Circulation 1993;88:71-81.
25. Abe J, Zhou W, Taguchi J. Supression of neointimal smooth muscle cell accumulation in vivo by antisense CDC2 and CKC2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun 1994;198:16-24.
26. Laughlan G, Murchie A, Norman D. The high-resolution crystal of a parallel-stranded guanine tetraplex. Science 1994;265:520-4.
27. Stein C, Krieg A. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxymicleotides. Antisense Res Dev 1994;4:67-9.
28. Morishita R, Gibbons G, Kaneda Y, Ogihara T, Dzay V. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 1994;149:13-9.